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Abstract 
 
One year of treatment with bisphosphonates at 5x the dose used for post-menopausal 
 
osteoporosis significantly increases failure load and microdamage, and decreases toughness 
 
at multiple skeletal sites in intact female beagles. The goal of this study was to determine if 
 
similar changes occur with doses equivalent to those used for PMO treatment. Skeletally- 
 
mature female beagles were treated daily for one year with vehicle (VEH) or one of three 
 
doses of risedronate (RIS; 0.05, 0.10, 0.50 mg/kg/day) or alendronate (ALN; 0.10, 0.20, 1.00 
 
mg/kg/day). Doses of ALN corresponded to treatment dose for PMO, ½ that dose, and 5x 
 
that dose on a mg/kg basis; RIS was given at a dose-equivalent to ALN. Vertebral density, 
 
geometry, percent ash, static/dynamic histology, microdamage, and biomechanical 
 
parameters were quantified. Trabecular bone activation frequency (Ac.f) was dose- 
 
dependently lower in RIS-treated groups (-40%, -66%, -84%, p < 0.05 vs VEH) while the 
 
three ALN groups were all similarly lower compared to VEH (-65%, -71%, -76%; p < 0.05). 
 
Crack surface density (Cr.S.Dn) was significantly higher than VEH for all doses of RIS and 
 
ALN (+2.9 to 5.4-fold vs VEH).  Stiffness was significantly increased with both agents while 
 
there were no significant changes in any other structural or estimated material properties. 
 
Cr.S.Dn and Ac.f exhibited a significant non-linear correlation (r
2 
=0.21; p<0.001) while 
 
there was no relationship between Cr.S.Dn and any mechanical properties. These results 
 
document that 1-year of bisphosphonate treatment at clinical doses allows significant 
 
accumulation of microdamage in the vertebra but this is offset by increases in bone volume 
 
and mineralization such that there is no significant impairment of mechanical properties. 45 
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INTRODUCTION 
 
Anti-remodeling drugs reduce fracture risk by altering both structural and material bone 
 
properties [1]. Suppressed bone remodeling enhances bone structure through increases in 
 
bone volume and maintenance of trabecular architecture [2, 3]. At the material level, 
 
remodeling suppression increases average tissue mineralization and tissue density 
 
homogeneity [4]. Biomechanically, these structural and material changes enhance whole 
 
bone strength and stiffness, yet increased mineralization is also negatively correlated to 
 
toughness [5-7]. A greater understanding of the net balance among structural and material 
 
alterations that occur with anti-remodeling treatment is necessary. 
 
We and others have documented that bisphosphonate administration at 5x the clinical 
 
dose for treatment of post-menopausal osteoporosis, increases trabecular bone volume, 
 
mineralization, ultimate load and stiffness in dog vertebra [8, 9]. However, remodeling 
 
suppression to levels produced by these doses also significantly increases microdamage 
 
accumulation and decreases bone toughness [8, 9]. These previous studies were designed to 
 
examine the role of remodeling suppression on microdamage and biomechanical properties, 
 
rather than the effects of individual bisphosphonate treatments, which have demonstrated 
 
anti-fracture efficacy [10]. The results have raised some concerns about long-term anti- 
 
remodeling therapies [11, 12], but the applicability of these data to clinical situations remains 
 
unclear because the bisphosphonate doses were 5- to 6-times the clinical dose used for 
 
treatment of post-menopausal osteoporosis. Although the degree of remodeling suppression 
 
in these dog studies was similar to that of post-menopausal women [13], it may represent 
 
over-suppression in a non-osteoporotic dog model that has slower bone turnover compared to 
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post-menopausal women. It is possible that the microdamage and toughness changes in the 
 
dog model are specific to the high doses used in these previous studies. 
 
The objective of this study was to quantify the changes in bone remodeling, microdamage 
 
accumulation, and biomechanical properties following 1-year treatment with bisphosphonate 
 
doses equivalent to those used for prevention/treatment of post-menopausal osteoporosis. 
 
Our hypothesis was these clinical treatment doses would allow significant increases in 
 
microdamage accumulation and reductions in toughness due to suppression of bone 
 
remodeling.  To test this hypothesis, skeletally mature female beagle dogs were treated daily 
 
for 1 year with either risedronate or alendronate at the clinical treatment dose (0.10 and 0.20 
 
mg/kg/day p.o, respectively), as well as lower and higher doses so that dose-response effects 
 
for damage accumulation and toughness could also be determined. Density, geometry, 
 
mineralization, remodeling, microdamage, and biomechanical properties of vertebral bone 
 
were quantified. 82 
MATERIALS AND METHODS 
 
Animals 
 
Eighty-four skeletally mature female beagles (1.3 ± 0.02 years old) were purchased from 
 
Marshall Farms USA (North Rose, NY).  Upon arrival, lateral X-rays of all dogs were 
 
obtained to confirm skeletal maturity (closed proximal tibia and lumbar vertebra growth 
 
plates). Animals were housed two per cage in environmentally controlled rooms at Indiana 
 
University School of Medicine’s AALAC accredited facility and provided standard dog 
 
chow and water. All procedures were approved prior to the study by the Indiana University 
 
School of Medicine Animal Care and Use Committee. 
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Experimental Design 
 
Following two weeks of acclimatization, animals were assigned to treatment groups 
 
(n=12/group) by matching body weights. All dogs were treated daily for 1-year with oral 
 
doses of vehicle (saline), risedronate sodium (Procter and Gamble Pharmaceuticals, Inc) or 
 
alendronate sodium (Merck and Co., Inc). Alendronate doses (0.10, 0.20, and 1.00 
 
mg/kg/day) were chosen to correspond with clinical doses used for post-menopausal 
 
osteoporosis.  The lower two doses are equivalent (on a mg/kg basis) to the preventative (5 
 
mg) and therapeutic (10 mg) doses of alendronate. Based on the ratios of in vivo potency 
 
100 (1:2) and clinical dose levels (2:1), dose-equivalents of risedronate were administered at 
 
101 doses of 0.05, 0.10, and 0.50 mg/kg/day. Both risedronate and alendronate were dissolved in 
 
102 saline and administered to the dogs orally with a syringe.  Vehicle-treated animals received 1 
 
103 ml/kg/day of saline. Dosing was performed each morning after an overnight fast and at least 
 
104 2 hours prior to feeding. 
 
105 Prior to necropsy, animals were injected with calcein (0.20 mL/kg, IV) using a 2-12-2-5 
 
106 labeling schedule (9 animals per group) or a 2-5-2-5 (3 animals per group).  The shorter 
 
107 interlabel duration was due to a scheduling error. Animals were euthanized by intravenous 
 
108 administration of sodium pentobarbital (0.22mg/kg Beuthanasia-D Special). After death, 
 
109 thoracic and lumbar vertebrae were dissected and saved for analyses. The ninth thoracic and 
 
110 fourth lumbar vertebrae were separately wrapped in saline-soaked gauze and frozen (-20ºC). 
 
111 Second and third lumbar vertebrae were fixed in 10% neutral buffered formalin. 
 
112 
 
113 
Densitometry 
 
Areal bone mineral density (aBMD, g/cm
2
) of the fourth lumbar vertebra (L4) was quantified 
 
114 using a PIXImus II densitometer (Lunar Corp.). Prior to scanning, the vertebrae were thawed 
6 
 
 
 
115 to room temperature. The posterior elements and cranial/caudal endplates were removed 
 
116 using a low speed diamond saw (Labcut 1010, Extec) under constant irrigation. Endplate 
 
117 removal was done such that surfaces were parallel for mechanical testing.  Scanning (0.18x 
 
118 0.18 mm/pixel) was performed with the vertebral body laying on its medial surface. For each 
 
119 specimen, aBMD of the entire vertebral body, excluding the posterior elements, was 
 
120 determined. 
 
121 Volumetric bone density and geometry of the L4 vertebra was quantified using a Norland 
 
122 Stratec XCT Research SA+ pQCT (Stratec Electronics). A scout view of each bone was 
 
123 obtained to determine slice locations. One slice (0.07 X 0.07 x 0.50 mm voxel size) was 
 
124 
 
125 
taken at three locations (25, 50 and 75% of total vertebra height).  Total and trabecular 
volumetric bone mineral density (vBMD, mg/cm
3
) and cross-sectional area (CSA, mm
2
) 
126 
 
127 
were obtained for each slice using contour mode 1, peel mode 2, and a threshold of 710 
mg/cm
3
.  Values from the three slices were averaged together to obtain a single 
128 representative value for each specimen. 
 
129 Percent Ash 
 
130 Percent ash was quantified from two regions of the ninth thoracic vertebrae. Vertebrae were 
 
131 
 
132 
thawed to room temperature and cut in half using a band saw (Marmed Inc.) under constant 
irrigation.  The caudal half was saved whole while a trabecular bone core (4 mm
3
) was cut 
133 from the mid-cranial metaphysis.  Specimens were dried using acetone/anhydrous ether and 
 
134 weighed daily until mass was stabilized for two consecutive days (dry weight). Bones were 
 
135 ashed at 800ºC for 12 hours using a 1400 Thermolyne oven (Barnstead). Ashed specimens 
 
136 were allowed to cool and then weighed (ash weight). Percent ash was calculated as ash 
 
137 weight/dry weight * 100. 
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138 Histology (Static, dynamic, and microdamage) 
 
139 Static and dynamic histomorphometric measures of trabecular bone were obtained on second 
 
140 lumbar vertebrae. After 3 days of fixation, bones were transferred to 70% ethanol until 
 
141 processing.  Using an automatic tissue processor (Shandon/Lipshaw), specimens were cycled 
 
142 through a graded series of ethanols, cleared using xylene, and infiltrated with methyl 
 
143 methacrylate (MMA; Aldrich).  Specimens were transferred to a solution of MMA + 3% 
 
144 
 
145 
dibutyl phthalate (DBP; Sigma-Aldrich) for 3-7 days under vacuum and then embedded 
using MMA + DBP + 0.25% catalyst (Perkadox 16
3
; Akzo Nobel Chemicals).  Mid-sagittal 
146 (4 µm) sections were cut using a Reichert-Jung 2050 microtome (Magee Scientific, Inc) and 
 
147 stained with McNeal’s tetrachrome for static histomorphometry. Mid-sagittal (8 µm) 
 
148 sections were cut and left unstained for dynamic histomorphometry and wall thickness 
 
149 measures. 
 
150 Third lumbar vertebrae were processed for microdamage assessment by bulk staining in 
 
151 basic fuchsin [14].  Using 1% basic fuchsin dissolved in increasing concentrations of ethanol, 
 
152 specimens were stained according to the following schedule: 8 hours 80% (with one change 
 
153 to fresh 80% after 4 hours), overnight in 95% (with one change to fresh 95%), 8 hours in 
 
154 100% (with one change to fresh 100% after 4 hours). Bones were placed under vacuum (20 
 
155 in Hg) for all stages during the day and left on the bench top overnight. Following staining, 
 
156 bones were washed 2x in 100% ethanol (five minutes each), placed in 100% MMA under 
 
157 vacuum for 4 hours, and then transferred to MMA + DBP for 3 days. Samples were 
 
158 embedded in MMA + DBP + 0.25% catalyst. Mid-sagittal (80-100 µm) sections were cut 
 
159 using a diamond wire saw (Histosaw; Delaware Diamond Knives). 
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160 Histological measurements were made using a semiautomatic analysis system (Bioquant 
 
161 OSTEO 7.20.10, Bioquant Image Analysis Co.) attached to a microscope equipped with an 
 
162 ultraviolet light source (Nikon Optiphot 2 microscope, Nikon).  Measurements were carried 
 
163 out on one stained (static), one unstained (dynamic), and two bulk stained (microdamage) 
 
164 sections per animal.  Analysis of a single stained and unstained section has been previously 
 
165 shown to be sufficient to detect significant differences in this animal model [8] while two 
 
166 sections were measured for microdamage variables to reduce the probability of crackless 
 
167 specimens [15]. A 5 x 5 mm region of interest, located 1 mm below the cranial plateau, was 
 
168 used for sampling.  Static and dynamic variables were measured and calculated in accordance 
 
169 with ASBMR recommended standards [16]. Microdamage was assessed using UV 
 
170 fluorescence as previously described [17]. Cracks were identified by their typical linear 
 
171 shape, relative size (greater than canaliculi, smaller than vascular channels), and positive 
 
172 fluorescence (due to diffusion of stain into the crack wall) (Figure 1). Microcracks were 
 
173 identified at 10x magnification and measured at 20x magnification. Measurements included 
 
174 
 
175 
crack length (Cr.Le, µm) and crack number (Cr.N), with calculations of crack density (Cr.Dn, 
 
#/mm
2
; Cr.N / bone area) and crack surface density (Cr.S.Dn, µm/mm
2
; Cr.N * Cr.Le / bone 
 
176 area). 
 
177 Biomechanical Testing 
 
178 The biomechanical properties of fourth lumbar vertebrae were quantified using a 
 
179 servohydraulic testing system (MTS 810, MTS Corporation). Following densitometry, 
 
180 vertebral height was measured using digital calipers (Starrett #721; L.S. Starrett Co). 
 
181 Compression to failure was carried out on saline soaked specimens using displacement 
 
182 control mode (20 mm/min). Load vs displacement curves were recorded using a HP-7090 
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183 plotting system. Plots were analyzed for determination of ultimate force (maximum force 
 
184 obtained during test) and stiffness (slope of the linear portion of load/displacement curve). 
 
185 Work to ultimate force (area under the load/displacement curve before ultimate force) was 
 
186 measured by digitizing plots and analyzing the area using standard imaging software (Scion 
 
187 Image; Scion Corp.).  Ultimate stress (σult), modulus (E), and toughness (U) were estimated 
 
188 using the following equations: 
 
189 σult = (ultimate force / CSA) / BV/TV 
 
190 E = (stiffness * (height / CSA)) / BV/TV 
 
191 U = (work to ultimate force / (height * CSA)) / BV/TV 
 
192 where cross sectional area is from pQCT measures of the same vertebrae (L4), height 
 
193 measured using digital calipers, and BV/TV from L2 histomorphometry. These equations 
 
194 have been previously used to estimate the material properties of canine vertebra [8, 9]. 
 
195 Statistics 
 
196 All statistical tests were performed using SAS software (SAS Institute, Inc.). Differences 
 
197 among all seven treatment groups were evaluated using a one-way analysis of variance 
 
198 (ANOVA), allowing evaluation between RIS and ALN at dose-equivalents. Additionally, 
 
199 separate ANOVAs were run for VEH+RIS and VEH+ALN to independently compare each 
 
200 drug (and dose) to vehicle-treated animals. When a significant overall F value (p < 0.05) was 
 
201 present, differences between individual group means were tested using Fisher’s protected 
 
202 least-significant difference (PLSD) post-hoc test. Simple linear or polynomial regression 
 
203 analyses were performed to test the relationship among activation frequency, percent ash, 
 
204 crack surface density, and toughness. For all tests, p < 0.05 was considered statistically 
 
205 significant. All data are presented as mean ± standard error. 
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206 
 
207 RESULTS 
 
208 There was no difference (both p > 0.90) among group body masses at baseline (overall 
 
209 average 8.30 ± 0.14 kg) or at the conclusion of the treatment (overall average 8.97 ± 0.16 
 
210 kg). All animals completed the one year of treatment without observable complication from 
 
211 the drugs. Two dosing errors occurred during the study. One dog in the high dose risedronate 
 
212 group (0.50 mg/kg/day) received a different drug (raloxifene, 0.5 mg/kg/day) for 2 days in 
 
213 
 
214 
the month prior to sacrifice. One dog in the low dose alendronate group (0.10 mg/kg/day) 
received the middle dose risedronate (0.10 mg/kg/day) for the entire 5
th 
month of treatment. 
215 These animals remained in all analyses as the values were within the variance of their 
 
216 respective groups. 
 
217 
 
218 
 
219 
Density, geometry, mineralization 
 
Areal bone mineral density (aBMD, g/cm
2
) was not significantly increased with treatment (p 
= 0.07; Table 1) while volumetric total bone mineral density (vBMD, mg/cm
3
) and 
 
220 volumetric trabecular BMD were both significantly increased compared to VEH (Table 1). 
 
221 Total vBMD was significantly higher (p = 0.03) than VEH for the middle and high doses of 
 
222 ALN while trabecular vBMD was significantly higher (p = 0.02) for the middle and high 
 
223 doses of RIS. There was no significant difference between any dose-equivalents of RIS and 
 
224 ALN, or within drug at the various doses, for any of the density variables. Total cross- 
 
225 sectional area of the vertebral body was not significantly changed with either RIS or ALN. 
 
226 Trabecular bone percent ash was significantly higher (+ 3 to +5 %) than VEH for the middle 
 
227 and high doses of RIS and all three doses of ALN (Table 1). Cortical plus trabecular bone 
 
228 percent ash was not significantly different than vehicle for RIS or ALN (+1 to +3% vs 
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229 vehicle). There was no difference among doses within drug, or between drugs at dose- 
 
230 equivalents, for percent ash. 
 
231 Static and dynamic histomorphometry 
 
232 Trabecular bone volume (BV/TV) was significantly higher with bisphosphonate treatment 
 
233 (Table 2). The low and high doses of RIS and all three doses of ALN were significantly 
 
234 higher than VEH (+5 to + 21%). Activation frequency (Ac.f) was significantly lower than 
 
235 vehicle-treated animals in all bisphosphonate-treated groups (Figure 2). The suppression of 
 
236 Ac.f was significantly less (-40%) in the low dose RIS group compared to both middle and 
 
237 high doses (-66 and -84%, respectively). Ac.f was also significantly higher in the low dose 
 
238 RIS group compared to its ALN dose-equivalent. All ALN groups had significantly lower 
 
239 Ac.f compared to vehicle (-65% to -76%) with no difference among the three doses. 
 
240 Activation frequency suppression resulted from reduced bone formation rate (BRF/BS) in all 
 
241 bisphosphonate groups; there was no significant difference in mean wall thickness among 
 
242 groups (Table 2). Reduced BFR/BS (-38 to -81%) resulted from a significant reduction in 
 
243 mineralizing surface (MS/BS); mineral apposition rate was not different among groups 
 
244 although it tended to be lower with both RIS (p = 0.07) and ALN (p = 0.06) compared to 
 
245 VEH. Risedronate dose-dependently suppressed MS/BS (-26, -51, and -75% for 0.05, 0.10, 
 
246 0.50 doses, respectively); all three ALN doses were similarly lower than vehicle-treated 
 
247 
 
248 
animals (-49 to -69%). MS/BS of the low dose RIS group was significantly higher than its 
dose-equivalent of ALN. There was a significant negative linear relationship (r
2 
=0.13; p = 
249 
 
250 
 
251 
0.008) between Ac.f and % ash of trabecular bone (%ash = -1.08(Ac.f) + 63.61). 
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252 Microdamage accumulation 
 
253 Risedronate and alendronate each increased the number of microcracks in vertebral 
 
254 trabecular bone, with no effect on mean crack length (Table 3). Crack density (Table 3) was 
 
255 significantly higher in all RIS-treated groups compared to VEH; the highest dose was 
 
256 significantly higher than both the low and middle dose of RIS.  The middle and high doses of 
 
257 ALN had significantly higher Cr.Dn compared to VEH; the highest dose was significantly 
 
258 greater than the lowest dose. Crack surface density (Figure 2) differences were similar to 
 
259 those of Cr.Dn. All three RIS groups had significantly higher Cr.S.Dn compared to VEH 
 
260 (+2.9 to +5.4-fold vs VEH) with the highest dose significantly higher than the lower two 
 
261 doses. ALN groups were all significantly higher than VEH (+3.1 to +4.7-fold vs VEH) with 
 
262 
 
263 
no significant difference among the doses. There was a significant negative non-linear 
relationship (Cr.S.Dn = 1.469 – 0.47(Ac.f) + 0.0005(Ac.f)2; r2 =0.21; p<0.001) between 
264 Cr.S.Dn and Ac.f (Figure 3); this relationship was similar for each drug separately. There 
 
265 was no difference in microdamage parameters between drugs at dose-equivalents. 
 
266 Biomechanical properties 
 
267 Neither ultimate load nor ultimate stress was significantly different among groups (Table 4). 
 
268 Stiffness was significantly higher than vehicle with both RIS (middle and high doses) and 
 
269 ALN (all three doses), while modulus was not significantly different among groups. There 
 
270 
 
271 
 
272 
 
273 
 
274 
was no significant difference among groups in work to ultimate load or toughness (Table 4). 
There was no correlation between toughness and crack surface density (r
2 
=0.006; p = 0.46). 
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275 DISCUSSION 
 
276 One-year of bisphosphonate treatment at doses equivalent to 5x the clinical dose for post- 
 
277 menopausal osteoporosis suppresses remodeling and increases trabecular bone volume, 
 
278 mineralization and stiffness in dogs [8, 9].  However, remodeling suppression to levels 
 
279 produced by these high doses also significantly increases microdamage accumulation and 
 
280 decreases toughness [8, 9]. These findings led to numerous questions regarding the 
 
281 relationship between remodeling suppression, microdamage, and biomechanical properties. 
 
282 The current study allows us to address specifically: 1) whether the extent of damage 
 
283 accumulation is related to the degree of remodeling suppression; 2) whether a level of 
 
284 remodeling suppression exists that allows targeted remodeling to limit microdamage 
 
285 accumulation; and 3) whether doses of risedronate or alendronate that are equivalent to those 
 
286 used for treatment of post-menopausal osteoporosis increase microdamage accumulation and 
 
287 decrease toughness in canine vertebra. 
 
288 Site-specific variations in microdamage have led to the proposal that the amount of 
 
289 damage accumulation is related to the level of remodeling suppression [18].  On an 
 
290 
 
291 
individual sample basis, the relationship between remodeling suppression and damage 
accumulation was significantly related in a non-linear fashion (r
2 
=0.21), similar to previous 
292 reports [8, 9]. However on a population basis (within individual treatment groups) a wide 
 
293 range of remodeling suppression (-40 to -84%) was associated with equivalent microdamage 
 
294 accumulation. For example, two treatment groups with significantly different reductions in 
 
295 activation frequency (RIS 0.05 (-40%) and RIS 0.10 (-66%)) both had a 2.9-fold increase in 
 
296 crack surface density. Conversely, two groups with roughly equivalent decreases in 
 
297 remodeling (ALN 0.2 (-71%) and ALN 1.0 (-76%)) had quite different crack surface 
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298 densities (+ 3.7 and + 4.7-fold higher than vehicle). These data suggest that, although as a 
 
299 general rule remodeling suppression increases microdamage, in treatment populations the 
 
300 extent of remodeling suppression is a poor marker of the amount of microdamage 
 
301 accumulation. This may be due to other factors that occur secondary to remodeling 
 
302 suppression (e.g. a change in matrix mineralization) that may play a larger role in 
 
303 determining microdamage accumulation than previously hypothesized [19, 20]. 
 
304 Alternatively, it could represent individual biological response to treatment, similar to 
 
305 findings in clinical trials [21, 22].  These studies have documented populations of 
 
306 “responders” and “non-responders” to bisphosphonate treatment as assessed using BMD and 
 
307 bone turnover biomarkers. Similar variability is plausible in animals (and humans) with 
 
308 respect to turnover suppression and microdamage accumulation. 
 
309 It has been suggested that remodeling suppression of less than 50% may limit 
 
310 microdamage accumulation [23, 24] by allowing a sufficient amount of targeted remodeling 
 
311 [25, 26]. In the current study only the lowest dose of risedronate (equivalent to half the dose 
 
312 for PMO treatment) reduced activation frequency less than this proposed threshold (-40% 
 
313 compared to vehicle). Crack surface density in this group was significantly higher (3-fold) 
 
314 than vehicle-treated animals, and not significantly different than the middle RIS dose or the 
 
315 dose-equivalent of ALN. Therefore, even mild suppression of trabecular bone remodeling in 
 
316 this canine model allows significant damage accumulation suggesting the threshold is below 
 
317 a 40% reduction. The level of remodeling suppression that allows microdamage 
 
318 accumulation may differ in post-menopausal women who have increased bone turnover prior 
 
319 to bisphosphonate treatment and likely differs depending on whether measured by histology 
 
320 or biomarkers. 
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321 It is well-accepted that bisphosphonates decrease fractures in at-risk populations [10, 27- 
 
322 30]. The current study supports these clinical observations by documenting non-significantly 
 
323 higher ultimate load and significantly higher vertebral stiffness in animals treated with RIS or 
 
324 ALN at doses equivalent to those used for treatment of post-menopausal osteoporosis. These 
 
325 enhanced structural properties, manifested through changes in bone density (bone volume 
 
326 and mineralization), are likely the mechanism responsible for large reduction in fracture risk. 
 
327 There was no significant difference among groups in energy to ultimate load or in any of the 
 
328 estimated material properties. It is important to note that these data represent estimated 
 
329 material properties, having different absolute values compared to those from isolated 
 
330 trabecular bone cores. However, values are comparable with previous studies in dog vertebra 
 
331 from our lab and others [8, 9, 18, 31]. Taken together, these data suggest an overall positive 
 
332 effect of bisphosphonate treatment at clinical dosing equivalents on the structural but not the 
 
333 material properties of vertebral bone. 
 
334 The absence of significant reductions in toughness, given the significant increase in 
 
335 microdamage accumulation, contradicts previous results that implicated microdamage 
 
336 accumulation as a principal determinant of toughness reduction with bisphosphonate 
 
337 treatment [8, 9, 18, 31]. These previous studies all utilized bisphosphonate doses that 
 
338 exceeded the clinical treatment dose by 2.5 to 6 times, suggesting that toughness reductions 
 
339 may be confined to high bisphosphonate dosing levels. Indeed, when the high dose groups of 
 
340 the current study are individually compared to VEH the differences in toughness approach, 
 
341 although still do not achieve, statistical significance compared to VEH (ALN, p = 0.06; RIS, 
 
342 p = 0.20). As a percent of VEH values, changes in the high dose groups (-13 and -17% for 
 
343 RIS 0.5 and ALN 1.0, respectively) were slightly less than our previous studies (-20% 
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344 compared to VEH) [8]. Based on these results it appears the toughness reductions with 
 
345 bisphosphonate treatment may be specific to some change brought about by high-dose 
 
346 regimens. However, it is hard to ignore the consistency of the non-significantly lower 
 
347 toughness values in all treatment groups compared to vehicle (-6 to -17%). The absence of 
 
348 relationship between crack surface density and toughness suggests that factors other than 
 
349 damage accumulation may be principally responsible for the reductions in toughness 
 
350 previously reported with bisphosphonate treatment [8, 9, 18]. 
 
351 Alendronate and risedronate are both nitrogen-containing bisphosphonates approved for 
 
352 treatment of post-menopausal osteoporosis (PMO). A head-to-head clinical trial has shown 
 
353 different degrees of BMD and biomarker changes with these two agents [21]. These two 
 
354 bisphosphonates have also been documented to exhibit different bone pharmacokinetic and 
 
355 binding properties [32, 33]. In the current study, we evaluated both drugs at various dose- 
 
356 equivalents based on the lower in vivo potency (1:2) and higher clinical dosing (2:1) of ALN 
 
357 vs RIS. Histological markers of bone turnover (MS/BS, BFR/BS and Ac.F) were suppressed 
 
358 significantly less in RIS-treated animals compared to the dose-equivalent of ALN at the 
 
359 lowest dose. In addition RIS demonstrated dose-dependency in Ac.f compared to ALN 
 
360 which decreased remodeling similarly at all three doses. At the lowest dose, equivalent on a 
 
361 mg/kg basis to the dose prescribed for prevention of post-menopausal osteoporosis, ALN 
 
362 suppressed Ac.f by 65%, not different from the 76% suppression at a dose 10x higher. 
 
363 Suppression of Ac.f with RIS more than doubled (-40 % to -84%; p < 0.05) between the 
 
364 lowest and the highest doses.  This suggests risedronate has a greater ability to finely regulate 
 
365 bone remodeling, a quality that may be beneficial in situations in which smaller reductions in 
 
366 turnover would be advantageous. Trabecular bone volume (BV/TV) was also significantly 
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367 different for the middle dose of the two drugs, with RIS being significantly lower than ALN. 
 
368 The reason for this is unclear but we believe it is not likely a true biological effect given that 
 
369 other skeletal sites in these dogs, such as the femoral neck, show increased BV/TV 
 
370 comparable to the dose-equivalent of ALN (data not shown). 
 
371 The results of this study should be considered in light of various limitations.  Use of 
 
372 intact, non-ovariectomized beagle dogs may limit the translation of these results to high 
 
373 turnover, low bone mass conditions such as post-menopausal osteoporosis. The interaction 
 
374 between estrogen-deficiency and bisphosphonate treatment is difficult to assess in dogs due 
 
375 to their low baseline estrogen levels and their failure to lose trabecular bone via increased 
 
376 remodeling with ovariectomy [34]. Our quantification of bone turnover and microdamage 
 
377 were confined to trabecular bone of the vertebral body while biomechanical properties were 
 
378 assessed for the entire vertebral body. It is possible that changes in the cortical shell, such as 
 
379 in bone turnover, microdamage, and/or other properties contributed to the biomechanical 
 
380 changes, although there was no significant change in cortical shell BMD assessed by pQCT 
 
381 (data not shown). 
 
382 The aim of this study was to determine the effects of bisphosphonate treatment at doses 
 
383 equivalent to those used for post-menopausal osteoporosis on various properties of canine 
 
384 vertebrae. Based on our results, we conclude that: 1) microdamage accumulation with 
 
385 bisphosphonate treatment is related to remodeling suppression in a non-linear fashion on an 
 
386 individual, but not population, basis; 2) suppression of remodeling by 40% with 
 
387 bisphosphonate treatment is still sufficient to allow significant accumulation of microdamage 
 
388 in the vertebra; and 3) although clinical treatment doses of alendronate and risedronate used 
 
389 for post-menopausal osteoporosis significantly increase microdamage accumulation after 1 
18 
 
 
 
390 year, enhanced bone volume and mineralization resulted in no significant impairment of 
 
391 
 
392 
mechanical properties in this canine model. 
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414 FIGURE 1:  Microcrack stained en block with basic fuchsin viewed under UV fluorescence. 
 
415 Vertebral microcracks were identified at 10x magnification (A) and measured at 20x 
 
416 
 
417 
magnification (B).  Scale bars = 100 µm. 
 
418 FIGURE 2:  Activation frequency and microdamage accumulation of vertebral trabecular 
 
419 bone. (A) Activation frequency was significantly lower than vehicle in all bisphosphonate- 
 
420 treated animals (p < 0.001). Risedronate (RIS) produced a dose-dependent suppression while 
 
421 alendronate (ALN) similarly suppressed activation frequency among the three doses. The 
 
422 lowest dose of RIS was significantly different from its ALN dose-equivalent. (B) Crack 
 
423 surface density was significantly higher than vehicle in all bisphosphonate-treated groups (p 
 
424 = 0.002). Both clinical doses of RIS were significantly lower than the highest dose; all three 
 
425 ALN doses were similarly higher than vehicle. There were not differences between 
 
426 equivalent doses of RIS and ALN. Data expressed as mean ± SE.  Values within each bar 
 
427 represent percent (A) or fold (B) difference vs vehicle. p < 0.05 versus vehicle (a); vs low 
 
428 
 
429 
dose within drug (b); vs middle dose within drug (c); vs dose equivalent (d). 
 
430 FIGURE 3:  Non-linear regression analysis between activation frequency (Ac.f) and crack 
 
431 surface density (Cr.S.Dn) in the lumbar vertebra. Decreased activation frequency is 
 
432 associated in a quadratic function with an increase in microdamage accumulation (p < 0.001). 
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